Loading...
You have changed your country from
to
. Please be aware that this will change the currency in the purchasing process.
Products:Epigenetics and Nuclear Signaling >> Chromatin Modifying Enzymes >> Acetylation >> HAT
Overview
Product name
HAT3 peptide
Protein description
Synthetic peptide surrounding amino acid 1991 of human HAT3. This peptide was used as an immunogen for ab41718 - HAT3 antibody.
Properties
Purification notes
86% pure peptide.
Form
Liquid
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage buffer
Preservative: 0.02% Sodium Azide
Constituents: 0.1% BSA, PBS, pH 7.2
Concentration
Concentration information loading...
Research areas
Epigenetics and Nuclear Signaling >> Chromatin Modifying Enzymes >> Acetylation >> HAT
Applications
Show applications key
Our Abpromise guarantee covers the use of ab41910 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking
Application notes
BL: Use at an assay dependent dilution. This peptide is used for blocking the antibody activity of HAT-3 (ab41718). It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30 minutes at 37 degrees C.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Protein info
Function
Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2.
Involvement in disease
Note=Chromosomal aberrations involving MYST3 may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with CREBBP; translocation t(8;22)(p11;q13) with EP300. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Inversion inv(8)(p11;q13) generates the MYST3-NCOA2 oncogene, which consists of the N-terminus part of MYST3/MOZ and the C-terminus part of NCOA2/TIF2. MYST3-NCOA2 binds to CREBBP and disrupts its function in transcription activation.
Note=A chromosomal aberration involving MYST3 is a cause of therapy-related myelodysplastic syndrome. Translocation t(2;8)(p23;p11.2) with ASXL2 generates a MYST3-ASXL2 fusion protein.
Sequence similarities
Belongs to the MYST (SAS/MOZ) family.
Contains 1 C2HC-type zinc finger.
Contains 1 H15 (linker histone H1/H5 globular) domain.
Contains 2 PHD-type zinc fingers.
Domain
The N-terminus is involved in transcriptional activation while the C-terminus is involved in transcriptional repression.
Post-translational
modifications
Autoacetylated.
Phosphorylated upon DNA damage, probably by ATM or ATR.
Cellular localization
Nucleus. Partially concentrated in subnuclear foci distinct from PML bodies, and excluded from the nucleoli.
Target information above from: UniProt accessionQ92794
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).
References for HAT3 peptide (ab41910)
ab41910 has not yet been referenced specifically in any publications.
Publishing research using ab41910? Please let us know so that we can cite the reference in this datasheet
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"